Floatz logo

Orteronel

Adenocarcinoma of the Prostate

University of Southern CaliforniaSmall moleculePhase 2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
81/ 100

Competitive context

97 Active assets in the Adenocarcinoma of the Prostate cohort.

Asset / SponsorPhaseRating
Docetaxel
Instituto do Cancer do Estado de São Paulo
Phase 3BBB
NILUTAMIDE
SWOG Cancer Research Network
Phase 3BB
Degarelix
Canadian Cancer Trials Group
Phase 3BB
PREDNISONE TABLETS
Mayo Clinic
Phase 3BB
Cyclophosphamide
Beijing Biotech
Phase 2BB

View all 50 →

Same molecule, other indications

Orteronel is also rated in:

prostate cancerDormant
B
Indicative ·
59 / 100
View asset →
prostate neoplasmDormant
CCC
Indicative ·
54 / 100
View asset →
hormone-resistant prostate carcinomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →